Released Nov 8, 2023, after the close
10-Q filed Nov 8, 2023, 39 days after period end · 0000950170-23-061080
Q3 2023 · 10-Q
Revenue$1.94M$1.94M −87.0% vs Q3 2022+108.4% vs Q2 2023
Net Income-$45.17M-$45.17M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.46-$0.46 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$51,279,000N/M
Operating Cash Flowderived-$38,273,000N/M
Free Cash Flowderived-$38,838,000N/M
Margins · derived
Operating margin-2637.8%−2061.1 pt vs Q3 2022
Net margin-2323.6%−1765.8 pt vs Q3 2022
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $1.94M | $14.98M | $14.23M | $7.56M |
| Net Income | -$45.17M | -$83.56M | -$43.31M | -$58.68M |
| EPS Diluted | -$0.46 | -$0.86 | -$0.45 | -$0.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR